Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis.

Y. C. Chung, M. T. Huang, C. N. Chang, T. W. Huang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Continuous hyperthermic peritoneal perfusion (CHPP) with anticancer agents in warm saline was performed in 10 patients with cancer of the digestive tract and peritoneal carcinomatosis after resection of primary and metastatic lesions or both. Eight patients had colorectal cancer and one patient had recurring gastric cancer. CHPP was performed using saline containing mitomycin-C and 5-flurouracil at 42 degrees C to 43 degrees C for 60 minutes. One patient with pancreatic cancer received CHPP twice. After CHPP, the preoperative ascites of three patients disappeared. Four patients died of malignancy within 1 year of CHPP and one patient died of respiratory failure 5 months post-CHPP. The remaining five patients survived for more than 1 year after CHPP. There were no significant immediate postoperative complications, except for transient changes in liver function, white blood cell count and serum albumin level. While CHPP treatment appears to be a safe method of treatment for peritoneal carcinomatosis, its long term benefits need further investigation.

Original languageEnglish
Pages (from-to)138-143
Number of pages6
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume95
Issue number2
Publication statusPublished - Feb 1996
Externally publishedYes

Fingerprint

Perfusion
Carcinoma
Mitomycin
Pancreatic Neoplasms
Leukocyte Count
Ascites
Serum Albumin
Respiratory Insufficiency
Antineoplastic Agents
Stomach Neoplasms
Gastrointestinal Tract
Colorectal Neoplasms
Neoplasms
Liver
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis. / Chung, Y. C.; Huang, M. T.; Chang, C. N.; Huang, T. W.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 95, No. 2, 02.1996, p. 138-143.

Research output: Contribution to journalArticle

@article{81a3aad725dd43b18f71adbb2d991586,
title = "Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis.",
abstract = "Continuous hyperthermic peritoneal perfusion (CHPP) with anticancer agents in warm saline was performed in 10 patients with cancer of the digestive tract and peritoneal carcinomatosis after resection of primary and metastatic lesions or both. Eight patients had colorectal cancer and one patient had recurring gastric cancer. CHPP was performed using saline containing mitomycin-C and 5-flurouracil at 42 degrees C to 43 degrees C for 60 minutes. One patient with pancreatic cancer received CHPP twice. After CHPP, the preoperative ascites of three patients disappeared. Four patients died of malignancy within 1 year of CHPP and one patient died of respiratory failure 5 months post-CHPP. The remaining five patients survived for more than 1 year after CHPP. There were no significant immediate postoperative complications, except for transient changes in liver function, white blood cell count and serum albumin level. While CHPP treatment appears to be a safe method of treatment for peritoneal carcinomatosis, its long term benefits need further investigation.",
author = "Chung, {Y. C.} and Huang, {M. T.} and Chang, {C. N.} and Huang, {T. W.}",
year = "1996",
month = "2",
language = "English",
volume = "95",
pages = "138--143",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Continuous hyperthermic peritoneal perfusion for peritoneal carcinomatosis.

AU - Chung, Y. C.

AU - Huang, M. T.

AU - Chang, C. N.

AU - Huang, T. W.

PY - 1996/2

Y1 - 1996/2

N2 - Continuous hyperthermic peritoneal perfusion (CHPP) with anticancer agents in warm saline was performed in 10 patients with cancer of the digestive tract and peritoneal carcinomatosis after resection of primary and metastatic lesions or both. Eight patients had colorectal cancer and one patient had recurring gastric cancer. CHPP was performed using saline containing mitomycin-C and 5-flurouracil at 42 degrees C to 43 degrees C for 60 minutes. One patient with pancreatic cancer received CHPP twice. After CHPP, the preoperative ascites of three patients disappeared. Four patients died of malignancy within 1 year of CHPP and one patient died of respiratory failure 5 months post-CHPP. The remaining five patients survived for more than 1 year after CHPP. There were no significant immediate postoperative complications, except for transient changes in liver function, white blood cell count and serum albumin level. While CHPP treatment appears to be a safe method of treatment for peritoneal carcinomatosis, its long term benefits need further investigation.

AB - Continuous hyperthermic peritoneal perfusion (CHPP) with anticancer agents in warm saline was performed in 10 patients with cancer of the digestive tract and peritoneal carcinomatosis after resection of primary and metastatic lesions or both. Eight patients had colorectal cancer and one patient had recurring gastric cancer. CHPP was performed using saline containing mitomycin-C and 5-flurouracil at 42 degrees C to 43 degrees C for 60 minutes. One patient with pancreatic cancer received CHPP twice. After CHPP, the preoperative ascites of three patients disappeared. Four patients died of malignancy within 1 year of CHPP and one patient died of respiratory failure 5 months post-CHPP. The remaining five patients survived for more than 1 year after CHPP. There were no significant immediate postoperative complications, except for transient changes in liver function, white blood cell count and serum albumin level. While CHPP treatment appears to be a safe method of treatment for peritoneal carcinomatosis, its long term benefits need further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0030073264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030073264&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 138

EP - 143

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 2

ER -